Summary
Vindesine (VDS) has been submitted to a phase-II trial, the results of which were assessed in terms of regression induction. VDS was given weekly IV in doses of 2 mg/m2 on two consecutive days to 59 patients, 55 of whom were evaluable. A high proportion of complete (36%) and over 50% partial regressions were obtained in acute lymphoid leukemias (ALL) (overall response 63%) whatever the perceptible phase, in blastic crisis of chronic myeloid leukemia (55%), and some responses were recorded in lymphosarcoma (40%). No effect has so far been seen in acute myeloid leukemia or in Hodgkin's disease. Malignant neoplasms of the immunoblastic type seem to be particularly sensitive to VDS. Continuous 48 h IV infusion can induce a remission where an IV push administration of the same dose has failed. One remarkable characteristic of VDS is the apparent absence of cross-resistance with VCR: in acute leukemic forms, 55% of patients who failed to obtain remission induction after three weekly injections of VCR (used in combination chemotherapy) achieved a complete or partial remission with VDS. The toxicity was mainly neurologic (paralytic ileus, constipation, paresthesias, loss of reflexes) and hematologic (leukopenia and thrombopenia), and was not more significant than with the other agents: four patients died of infection or hemorrhage.
Similar content being viewed by others
References
Barnett, C. J., Cullinan, G. J., Gerzon, K., Hoying, R. C., Jones, W. E., Newlon, W. M., Poore, G. A., Robinson, R. L., Sweeney, M. J., Todd, G. C., Dyke, R. W., Nelson, R. L.: Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Desacetylvinblastine amide (vindesine) sulfate. J. Med. Chem. 21, 88 (1978)
Clarysse, A., Kenis, Y., Mathé, G.: Cancer chemotherapy. Its role in the treatment strategy of hematologic malignancies and solid tumors. Heidelberg-New York. Springer (1976)
Clinical Screening Cooperative Group of EORTC: A phase-II clinical trial of peptichemio. Biomedicine 27, 290 (1977)
Currie, V., Wong, P., Tan, R., Tan, C., Krakoff, I.: Preliminary clinical studies of desacetyl vinblastine amide sulfate (DVA), a new vinca alkaloid. Proc. Am. Assoc. Cancer Res. 17, 174 (Abstract 694) (1976)
Donoso, J. A., Green, L. S., Heller-Bettinger, I. E., Samson, F.E.: Action of the vinca alkaloids vincristine, vinblastine and desacetyl vinblastine amide on axomal fibrillar organelles in vitro. Cancer Res. 37 1401 (1977)
Mathé, G., Misset, J. L., De Vassal, F., Gouveia, J., Hayat, M., Machover, D., Belpomme, D., Pico, J. L., Schwarzenberg, L., Ribaud, P., Musset, M., Jasmin, C., De Luca, L.: Phase II clinical trial with vindesine for remission induction in acute leukemia, blastic crisis of chronic myeloid leukemia, lymphosarcoma and Hodgkin's disease: absence of cross-resistance with vincristine. Cancer Treat. Rep. 62, 805 (1978)
Mathé, G., Misset, J. L., Gil, M., Delgado, M., De Vassal, F.: Leukaemic (or stage V) lymphosarcoma. In: Lymphoid neoplasias. Mathé, G., Seligmann, M., Tubiana, M. (eds.), pp. 86–105. Berlin, Heidelberg, New-York: Springer 1978
Mathé, G., Rappaport, H. (with the assistance of G. T. O'Conor and H. Torloni). Histological and cytological typing of neoplastic diseases of haematopoietic and lymphoid tissues, Vol. 14. Geneva: World Health Organization (1976)
Mathé, G., Weiner, R.: Criteria for short-term results in the treatment of acute leukemia. In: Nomenclature, methodology and results of clinical trials in acute leukemias. Mathé, G., Pouillart, P., Schwarzenberg, L. (eds.), pp. 110–112. Berlin, Heidelberg, New-York. Springer 1973
Nelson, R. L., Dyke, R. W., Root, M. A.: Comparative pharmacokinetics of the vinca alkaloids in man. In: Proceedings of the 78th Annual Meeting of the American Scciety for Clinical Pharmacology and Therapeutics, Dallas, 1977
Sweeney, M. J., Boder, G. B., Cullinan, G. J., Culp, H. W., Daniels, W. D., Gerzon, K., McMahon, R. E., Nelson, R. L., Poore, G. A., Todd, G. C.: Antitumor activity of desacetyl vinblastine amide sulfate (vindesine) in rodents and mitotic accumulation studies in culture. Cancer Res. 28, 2886 (1978)
Tan, C.: Clinical and pharmacokinetic studies of vindesine (DVA) in 35 children with malignant diseases. Curr. Chemother. 2, 1326 (1978)
Todd, G. C., Gubson, R., Morton, D. M.: Toxicology of vindesine (desacetyl vinblastine amide) in mice, rats and dogs. J. Toxicol. Environ. Health 1, 843 (1976)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bayssas, M., Gouveia, J., Ribaud, P. et al. Phase-II trial with vindesine for regression induction in patients with leukemias and hematosarcomas. Cancer Chemother. Pharmacol. 2, 247–255 (1979). https://doi.org/10.1007/BF00257189
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00257189